Chromatin/Epigenetics
Chromatin/epigenetics inhibitors are compounds that modulate the structure and function of chromatin or interfere with epigenetic modifications, such as DNA methylation and histone modification. These inhibitors are essential tools for studying gene expression regulation and the role of epigenetics in diseases like cancer, neurological disorders, and developmental abnormalities. By targeting epigenetic processes, these inhibitors can alter gene expression patterns and offer new therapeutic avenues. At CymitQuimica, we provide a wide selection of high-quality chromatin/epigenetics inhibitors to support your research in molecular biology, genetics, and epigenetics.
Subcategories of "Chromatin/Epigenetics"
Found 2235 products of "Chromatin/Epigenetics"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
KCL-440
CAS:<p>RS 57639 is a bioactive chemical.</p>Formula:C18H18N2O2Color and Shape:SolidMolecular weight:294.35BPTF-IN-BZ1
<p>BPTF-IN-BZ1 is a BPTF inhibitor that possesses a high potency with a Kd of 6.3 nM.</p>Formula:C13H15ClN4OColor and Shape:SolidMolecular weight:278.74XY153
<p>XY153 (8l) is a BD2 selective BET inhibitor targeting BRD4, 3 & 2 with IC50s: 0.79, 5.31 & 5.09 nM, useful in acute myeloid leukemia & cancer research.</p>Formula:C33H34FN3O4Color and Shape:SolidMolecular weight:555.64JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62Azaphilone-9
CAS:<p>AZA-9 inhibits cancer growth by blocking HuR-ARE RNA binding; IC50=1.2μM.</p>Formula:C21H23BrO5Color and Shape:SolidMolecular weight:435.3115:0 PG sodium
CAS:<p>15:0 PG sodium serves as an activator for the Protein Kinase C family and is an anionic phospholipid located in the membranes of mitochondria and microsomes. It plays a crucial role in the composition of pulmonary surfactants, especially within the membrane of the pulmonary lamellar bodies.</p>Formula:C36H70NaO10PColor and Shape:SolidMolecular weight:716.90PRMT5-IN-3
CAS:<p>PRMT5-IN-3 is a PRMT5 inhibitor.PRMT5-IN-3 is a combined DNA damaging agent that is synthetically lethal to tumor cells.</p>Formula:C22H23F3N4O3Color and Shape:SolidMolecular weight:448.44GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Formula:C20H18F2N6O5SColor and Shape:SolidMolecular weight:492.46P300-IN-4
<p>P300-IN-4 (compound 6) is a histone acetyltransferase p300 inhibitor with an IC50 value of 12.2 μM.</p>Formula:C29H28ClIN4O5Color and Shape:SolidMolecular weight:674.91Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Formula:C24H25N7O2Color and Shape:SolidMolecular weight:443.50ROPA
CAS:<p>ROPA, a potent PKCalpha and PKCgamma activator, promotes tumor growth through PKC-activation.</p>Formula:C28H32O6Purity:98%Color and Shape:SolidMolecular weight:464.55CBP/p300-IN-18
<p>CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).</p>Formula:C25H27FN4O3Color and Shape:SolidMolecular weight:450.51BET-IN-27
CAS:<p>BET-IN-27 (compound 6C) is an orally active BET inhibitor with IC50 values of 3.3 nM (BRD4-BD2), 3.4 nM (BRD4-BD1), 4.1 nM (BRD2-BD1), 20.4 nM (BRD3-BD1), and 42.0 nM (BRDT-BD1). It also exhibits antiproliferative activity.</p>Formula:C21H23N5O3SColor and Shape:SolidMolecular weight:425.5HDAC/Top-IN-1
CAS:<p>HDAC/Top-IN-1, an oral HDAC/Top inhibitor, targets HDAC1-3,6,8 with low IC50s; blocks S-phase & induces apoptosis in HEL cells.</p>Formula:C29H25FN4O4Color and Shape:SolidMolecular weight:512.53JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formula:C20H15ClF3N3OSColor and Shape:SolidMolecular weight:437.87BBC0403
CAS:<p>BBC0403 is a BRD2 inhibitor, inhibiting BRD2 and BRD2, and suppresses NF-κB and MAPK signaling pathways.</p>Formula:C21H22N2O5Purity:98.15%Color and Shape:SolidMolecular weight:382.41JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64XP5
<p>XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).</p>Formula:C19H25N3O5SColor and Shape:SolidMolecular weight:407.48(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formula:C20H27ClN6OColor and Shape:SolidMolecular weight:402.92PARP1-IN-30
CAS:<p>PARP1-IN-30 is a specific and effective PARP1 inhibitor with cytotoxic properties. It precisely inhibits PARP1 in tumor cells lacking breast cancer 1 protein (BRCA1) or BRCA2. PARP1-IN-30 holds potential for use in cancer research.</p>Formula:C14H12ClNO4SColor and Shape:SolidMolecular weight:325.77KSQ-4279 (gentisate)
CAS:<p>KSQ-4279 (gentisate) (Compound Formula I) serves as an effective inhibitor of USP1 and a selective inhibitor of PARP1. This compound shows promise for use in cancer research.</p>Formula:C34H31F3N8O5Color and Shape:SolidMolecular weight:688.66HIF-1/2α-IN-1
<p>HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.</p>Formula:C17H16N6O4Color and Shape:SolidMolecular weight:368.35(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37W4275
CAS:<p>W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.</p>Formula:C25H36N6O3Color and Shape:SolidMolecular weight:468.59GSK789
CAS:<p>GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.</p>Formula:C26H33N5O3Color and Shape:SolidMolecular weight:463.57PARP10/15-IN-1
<p>PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].</p>Formula:C13H10N2O3SColor and Shape:SolidMolecular weight:274.3PAD-IN-2
CAS:<p>PAD-IN-2, potent PAD4 inhibitor, IC50 <1 μM; targets autoimmune/cancer disorders.</p>Formula:C27H28ClN5O2Color and Shape:SolidMolecular weight:490RK-582
CAS:<p>RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.</p>Formula:C27H35FN6O3Color and Shape:SolidMolecular weight:510.6HDAC1-IN-8
CAS:<p>HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.</p>Formula:C22H24N2O4Color and Shape:SolidMolecular weight:380.437HDAC/HSP90-IN-4
<p>HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.</p>Formula:C20H23N3O6Color and Shape:SolidMolecular weight:401.15869TDI-015051
CAS:<p>TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.</p>Formula:C22H22FN5O4SColor and Shape:SolidMolecular weight:471.505(Rac)-RG108
CAS:<p>(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.</p>Formula:C19H14N2O4Color and Shape:SolidMolecular weight:334.326JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47AZ0108
CAS:<p>AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.</p>Formula:C24H20F4N6O2Color and Shape:SolidMolecular weight:500.45Dot1L-IN-1
CAS:<p>The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.</p>Formula:C32H36ClN9O2SPurity:98%Color and Shape:SolidMolecular weight:646.21PARP14 inhibitor 1
CAS:<p>PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.</p>Formula:C23H27FN4O3Color and Shape:SolidMolecular weight:426.484LSD1/2-IN-3
<p>LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.</p>Formula:C9H8BrF2NColor and Shape:SolidMolecular weight:248.07G-631
CAS:<p>G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.</p>Formula:C19H22F2N6O3Color and Shape:SolidMolecular weight:420.41AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Formula:C17H13ClFN5OColor and Shape:SolidMolecular weight:357.77AZ13824374
<p>AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.</p>Formula:C30H39FN8O2Color and Shape:SolidMolecular weight:562.68LSD1-IN-13 hydrochloride
CAS:<p>LSD1-IN-13 hydrochloride (7e) is an oral LSD1 inhibitor (IC50: 24.43 nM), promoting differentiation in AML cell lines.</p>Formula:C23H30ClN3O2SColor and Shape:SolidMolecular weight:448.02LSD1-IN-35
CAS:<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>Formula:C25H26N4O2SColor and Shape:SolidMolecular weight:446.57SMARCA2/4-ligand-5
CAS:<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Formula:C20H13ClN4O3Color and Shape:SolidMolecular weight:392.795PARP1-IN-29
CAS:<p>PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.</p>Formula:C18H16FN3O2Color and Shape:SolidMolecular weight:325.34LSD1-IN-17
<p>LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.</p>Formula:C20H18N2OSColor and Shape:SolidMolecular weight:334.43TY-011
CAS:<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Formula:C18H16ClN5Color and Shape:SolidMolecular weight:337.81PRMT5-IN-21
<p>PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.</p>Formula:C18H18F2N6O3Color and Shape:SolidMolecular weight:404.37Menin-MLL inhibitor 4
CAS:<p>Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .</p>Formula:C32H38FN7O3Purity:98%Color and Shape:SolidMolecular weight:587.69KAT6A-IN-2
CAS:<p>KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.</p>Formula:C23H29N5O5SColor and Shape:SolidMolecular weight:487.57AMI-408
CAS:<p>AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.</p>Formula:C20H13Cl2N6NaO5SColor and Shape:SolidMolecular weight:543.32KAT6A-IN-1
CAS:<p>KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.</p>Formula:C23H27N5O5SColor and Shape:SolidMolecular weight:485.56HLCL-61
CAS:<p>HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).</p>Formula:C23H24N2OColor and Shape:SolidMolecular weight:344.45LSD1-IN-16
<p>LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.</p>Formula:C20H18N2OSColor and Shape:SolidMolecular weight:334.43Bromodomain inhibitor-13
CAS:<p>Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.</p>Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.43CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36SMARCA2-IN-2
CAS:<p>Compound I-25, also known as SMARCA2-IN-2, is a SMARCA2 inhibitor (IC 50: 101-500 μM) with applications in cancer research.</p>Formula:C16H17N3Color and Shape:SolidMolecular weight:251.33AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32PFI-6-COOH
CAS:<p>PFI-6-COOH (Compound 18) is a ligand for the eleven-nineteen leukemia (ENL) protein, and is utilized in the synthesis of the ENL PROTAC degrader MS41.</p>Formula:C23H21N3O6Color and Shape:SolidMolecular weight:435.43NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Formula:C22H28N2O3Color and Shape:SolidMolecular weight:368.47cis-4-Br-2,5-F2-PCPA
<p>cis-4-Br-2,5-F2-PCPA (S1024) blocks LSD1/LSD2 (Ki: 94 nM/8.4 μM), hinders cancer stem cell growth, raises H3K4me2 in CCRF-CEM cells.</p>Formula:C9H8BrF2NColor and Shape:SolidMolecular weight:248.07YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Formula:C32H34F3N7O2Color and Shape:SolidMolecular weight:605.65Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40CBP/p300-IN-2
CAS:<p>CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).</p>Formula:C27H29F2N7O2Purity:98%Color and Shape:SolidMolecular weight:521.56PRMT5-IN-1
CAS:<p>PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).</p>Formula:C19H19ClN4O5Purity:98%Color and Shape:SolidMolecular weight:418.83PARP1/2-IN-4
CAS:<p>PARP1/2-IN-4 (compound 3) is an inhibitor of PARP1/2.</p>Formula:C23H30FN5O6Color and Shape:SolidMolecular weight:491.51LSD1/HDAC-IN-1
CAS:<p>LSD1/HDAC-IN-1 (compound 2) serves as an effective inhibitor of both HDAC and LSD1, demonstrating IC50 values of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8, and LSD1 respectively. This compound plays a crucial role in cancer research.</p>Formula:C18H18N2O4SColor and Shape:SolidMolecular weight:358.41DCHC
CAS:<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Formula:C15H8Cl2O3Color and Shape:SolidMolecular weight:307.128SCR-7952
CAS:<p>SCR-7952, a MAT2A inhibitor, is utilized in cancer research.</p>Formula:C19H15ClN4OColor and Shape:SolidMolecular weight:350.80XP-524
CAS:<p>XP-524: BET & EP300 inhibitor, suppresses KRAS tumors in vivo, targets PDAC, boosts immune response.</p>Formula:C30H28N6O3SColor and Shape:SolidMolecular weight:552.65PARP14 inhibitor 2
CAS:<p>PARP14 inhibitor2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of less than 30 nM. It effectively inhibits the mono ADP-ribosyltransferase activity of PARP14 and modulates IFN-γ and IL-4 signaling, thereby reversing pro-tumor macrophage polarization and suppressing anti-tumor inflammatory responses. PARP14 inhibitor2 holds potential for research in PARP14-related conditions such as tumors, atopic dermatitis, and autoimmune diseases.</p>Formula:C25H32FN3O4SColor and Shape:SolidMolecular weight:489.60MS8815
CAS:<p>MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.</p>Formula:C65H87N9O8SColor and Shape:SolidMolecular weight:1154.51PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Formula:C31H31FN8O2Purity:98%Color and Shape:SolidMolecular weight:566.63BET-IN-6
CAS:<p>BET-IN-6: Potent BRD2/4 inhibitor and ligand for PROTAC BRD2/BRD4 degrader-1 synthesis.</p>Formula:C22H20N2O6SPurity:98%Color and Shape:SolidMolecular weight:440.47PRMT5-IN-19
<p>PRMT5-IN-19 is a potent, selective PRMT5 inhibitor with IC50 of 23.9 nM and 47 nM, showing anti-cancer activity by inducing apoptosis.</p>Formula:C25H24N4OColor and Shape:SolidMolecular weight:396.48Itareparib
CAS:<p>Itareparib is a PARP inhibitor with demonstrated antitumor activity.</p>Formula:C20H26FN3O2Color and Shape:SolidMolecular weight:359.438HIF-1α-IN-4
<p>HIF-1α-IN-4 is an inhibitor of HIF-1α with IC50 of 24 nM in HEK293T cells which has potential antitumor effects.</p>Formula:C16H12N2O3Color and Shape:SolidMolecular weight:280.28HIF-2α-IN-7
CAS:<p>HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor.</p>Formula:C18H9F6NO2Color and Shape:SolidMolecular weight:385.26TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Formula:C24H20FN7O4Color and Shape:SolidMolecular weight:489.458(1-Nitroethene-1,2-diyl)dibenzene
CAS:<p>(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) serves as an inhibitor of protein arginine methyltransferase 1 (PRMT1; histone H4 methylation assay with an IC50 of 11 μM). At concentrations of 10 and 100 μM, it also inhibits histone H4 methylation caused by PRMT8 but does not affect methylation of histone H3.1 induced by CARM1 or Set7/9.</p>Formula:C14H11NO2Color and Shape:SolidMolecular weight:225.24Trichostatin A S-isomer
CAS:<p>Trichostatin A S-isomer, a HDAC 1, 3, 4, 6, 10 inhibitor with IC50 ~20 nM, has wide-ranging epigenetic effects.</p>Formula:C17H22N2O3Purity:98%Color and Shape:SolidMolecular weight:302.37OM-153
CAS:<p>OM-153 blocks tankyrase 1 (IC50: 13 nM) and 2 (IC50: 2 nM), stifling WNT signaling and COLO 320DM cell growth.</p>Formula:C28H24FN7O2Color and Shape:SolidMolecular weight:509.53CM-414
CAS:<p>CM-414: HDAC/PDE5 inhibitor, targeting Alzheimer’s, IC50s: PDE5 (60 nM), HDAC1/2/3/6. Reduces Aβ, pTau in mice, boosts cognition.</p>Formula:C23H29N5O4Purity:98%Color and Shape:SolidMolecular weight:439.51RL5a
CAS:<p>RL5a (compound C23) is a novel inhibitor of SETD8.</p>Formula:C17H19N3OColor and Shape:SolidMolecular weight:281.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37HDAC-IN-47
<p>HDAC-IN-47: Oral HDAC inhibitor (IC50: 19.75-302.73 nM for HDAC1-8), blocks G2/M, inhibits autophagy, triggers apoptosis, anti-cancer in vivo.</p>Formula:C17H20BrN3O4Color and Shape:SolidMolecular weight:410.26JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Formula:C23H22Cl2N4OColor and Shape:SolidMolecular weight:441.35HDAC8-IN-2
<p>HDAC8-IN-2 (5o) inhibits both smHDAC8 and hHDAC8 with IC50s of 0.27 μM, 0.32 μM, kills schistosome larvae, and lowers egg laying.</p>Formula:C21H16N2O5Color and Shape:SolidMolecular weight:376.36Enzomenib
CAS:<p>Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.</p>Formula:C33H43FN6O3Color and Shape:SolidMolecular weight:590.73MI-1481
CAS:<p>MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.</p>Formula:C29H30F3N7O2SPurity:98%Color and Shape:SolidMolecular weight:597.65HDAC3-IN-3
CAS:<p>HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].</p>Formula:C26H22N4O2Color and Shape:SolidMolecular weight:422.48WW437
<p>WW437 is a histone deacetylase (HDAC) inhibitor that exhibits potent anti-breast cancer activity both in vitro and in vivo.</p>Formula:C23H27N5O4Color and Shape:SolidMolecular weight:437.49MMSET-IN-1
CAS:<p>MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .</p>Formula:C18H29N7O5Purity:98%Color and Shape:SolidMolecular weight:423.47Equisetin
CAS:<p>Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.</p>Formula:C22H31NO4Purity:98%Color and Shape:SolidMolecular weight:373.49PAD4-IN-5
CAS:<p>PAD4-IN-5 (Example 18) is a PAD4 inhibitor with an IC50 of ≤10 nM at 50 µM Ca2+ and 101-500 nM at 1 mM Ca2+ against human PAD4 (hPAD4). This compound is applicable in the study of autoimmune diseases such as rheumatoid arthritis (RA).</p>Formula:C34H41N7O3Color and Shape:SolidMolecular weight:595.734LSD1-IN-18
<p>LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).</p>Formula:C31H40N6O2Color and Shape:SolidMolecular weight:528.69(2S,3R)-LP99
CAS:<p>(2S,3R)-LP99 is a less active enantiomer of LP99.</p>Formula:C26H30ClN3O4SPurity:98%Color and Shape:SolidMolecular weight:516.05HDAC-IN-32
<p>HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.</p>Formula:C20H23N3O3Color and Shape:SolidMolecular weight:353.41AFM-30a hydrochloride
<p>AFM-30a hydrochloride: selective PAD2 inhibitor, EC50 9.5 μM; blocks H3 guanylation, EC50 0.4 μM; used for cancer and autoimmune research.</p>Formula:C24H28ClFN6O3Color and Shape:SolidMolecular weight:502.97GSK3368715
CAS:<p>GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s</p>Formula:C20H38N4O2Purity:98%Color and Shape:SolidMolecular weight:366.54FT001
CAS:<p>FT001: Oral BET Bromodomain inhibitor, IC50=0.46μM, suppresses MYC, anti-cancer, effective in vitro/vivo.</p>Formula:C25H29N3O4SPurity:99.9%Color and Shape:SolidMolecular weight:467.58NPC26
CAS:<p>NPC26 is a small molecule that disrupts mitochondrial function and exhibits antitumor activity. It shows significant antiproliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 induces mitochondrial permeability transition pore (mPTP) opening, generates reactive oxygen species (ROS), and triggers cell death. Additionally, NPC26 kills CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.</p>Formula:C19H23N3O5S2Color and Shape:SolidMolecular weight:437.533Aurora/LIM kinase-IN-1
<p>Aurora/LIM kinase-IN-1 (Compound F114) is a dual inhibitor targeting aurora and lim kinases, potentially useful in GBM cancer treatment efforts.</p>Formula:C16H20N6OColor and Shape:SolidMolecular weight:312.37BRD4 Inhibitor-32
CAS:<p>BRD4 Inhibitor-32 (example 15), a BRD4 inhibitor, is applicable in research pertaining to both acute and chronic kidney disease [1].</p>Formula:C26H25N3O3Color and Shape:SolidMolecular weight:427.5SGC6870N
CAS:<p>SGC6870N is inactive against PRMT6 and can be used as a negative control. It is the inactive enantiomer of SGC6870.</p>Formula:C23H21BrN2O2SMolecular weight:469.39PF-06726304 acetate
CAS:<p>PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity.</p>Formula:C24H25Cl2N3O5Purity:98%Color and Shape:SolidMolecular weight:506.38GNE-886
CAS:<p>GNE-886 has a wide range of applications in life science related research.</p>Formula:C28H30N6O3Purity:98%Color and Shape:SolidMolecular weight:498.59HuR degrader 2
CAS:<p>HuRdegrader 2 (Compound 3) is a molecular glue that targets and degrades the RNA-binding protein Hu antigen R (HuR), achieving 30% degradation at 0.1 μM. It inhibits the proliferation of Colo-205 cancer cells with an IC50 of ≤200 nM. HuRdegrader 2 also shows high affinity for cereblon with an HTRF ratio < 0.02.</p>Formula:C20H15N3O3Molecular weight:345.35MAT2A-IN-24
CAS:<p>MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a), with an IC50 value of 20 nM for MAT2a inhibition and an antiproliferative IC50 value of 10 nM for HAP1MTAP–/– cells. MAT2A-IN-24 is applicable in the research of tumor diseases associated with MTAP deficiency.</p>Formula:C32H33Cl2N7O2Color and Shape:SolidMolecular weight:618.556M-525
CAS:<p>M-525, a potent first-in-class menin-MLL inhibitor, binds at 3 nM IC50 and curbs MLL leukemia cell growth & gene expression.</p>Formula:C39H51FN6O5SPurity:98%Color and Shape:SolidMolecular weight:734.92Glycyl H-1152 hydrochloride
CAS:<p>Glycyl-H-1152 is a potent ROCK-II inhibitor (IC50=11.8 nM) with high selectivity over CaMKII, PKG, Aurora A, PKA, and PKC. Better than Y-27632 and HA-1077.</p>Formula:C18H26Cl2N4O3SColor and Shape:SolidMolecular weight:449.39HDAC6-IN-3
<p>HDAC6-IN-3 (Compound 14) is an oral anti-prostate cancer agent, inhibiting HDACs and MAO-A, with IC50 of 0.02-1.54 μM.</p>Formula:C19H27N3O3Color and Shape:SolidMolecular weight:345.44PARP7-IN-23
CAS:<p>PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells, indicating its potential for cancer research.</p>Formula:C27H22F7N5O3Color and Shape:SolidMolecular weight:597.484JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59RK-0080552
CAS:<p>RK-0080552 (RK-552) is an inhibitor of the NSD2 histone methyltransferase. It demonstrates significant cytotoxicity against multiple myeloma (MM) cells harboring the t(4;14) translocation. This compound suppresses the IRF4 gene and decreases the dimethylation of histone H3 at lysine 36. RK-0080552 holds promise for research in hematologic malignancies.</p>Formula:C12H6N6O2Color and Shape:SolidMolecular weight:266.215Octyl-α-hydroxyglutarate
CAS:<p>Octyl-α-hydroxyglutarate (octyl-2-HG) enhances histone methylation and boosts the viability of LMP1-negative nasopharyngeal carcinoma (NPC) cells.</p>Formula:C13H24O5Molecular weight:260.33GSK852
<p>GSK852 is a potent, second bromodomain (BD2)-selective, bromo and extra-terminal domain (BET) inhibitor with pIC50 of 7.9.</p>Formula:C24H26N2O4Color and Shape:SolidMolecular weight:406.47iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Formula:C19H15F3N2O2Color and Shape:SolidMolecular weight:360.33BRD4/NAMPT-IN-1
CAS:<p>BRD4/NAMPT-IN-1 (Compound A2) exhibits strong inhibitory effects on NAMPT and BRD4, with IC50 values of 35 nM (NAMPT) and 58 nM (BRD4). This compound significantly suppresses the growth and migration of liver cancer cells while promoting apoptosis. Additionally, BRD4/NAMPT-IN-1 demonstrates potent anticancer activity in HCCLM3 xenograft mouse models without noticeable toxicity.</p>Formula:C30H30ClN7O2SMolecular weight:588.12RU-0415529
CAS:<p>RU-0415529 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (NSP14), with an IC50 of 356 nM. It inhibits viral RNA methylation and replication by stabilizing the cap-binding pocket through SAH binding. Additionally, RU-0415529 exhibits anti-infective activity in mouse models.</p>Formula:C21H29N3O4SColor and Shape:SolidMolecular weight:419.538PKCiota-IN-1
CAS:<p>PKCiota-IN-1: Strong PKC-ι inhibitor (IC50=2.7 nM); also blocks PKC-α/ε (IC50s=45/450 nM).</p>Formula:C25H22FN5OColor and Shape:SolidMolecular weight:427.47AR/BET protein degrader-1
CAS:<p>AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.</p>Formula:C43H44N6O5Molecular weight:724.85HIF-1α-IN-5
<p>HIF-1α-IN-5 is an inhibitor of HIF-1α with an IC 50 value of 24 nM in HEK293T cells that also inhibits the activity of MAO-A.</p>Formula:C16H15N3O2Color and Shape:SolidMolecular weight:281.31Hesperadin hydrochloride
<p>Hesperadin hydrochloride is an ATP-competitive indolone inhibitor of Aurora A and B, with an IC50 value of 250 nM for Aurora B.</p>Formula:C29H33ClN4O3SColor and Shape:SolidMolecular weight:553.12Triciferol
CAS:<p>Triciferol is a VDR agonist and HDAC antagonist with 1,25D-like potency, affecting gene targets and tubulin, and shows anti-cancer effects in vitro. IC50=87nM.</p>Formula:C26H39NO4Color and Shape:SolidMolecular weight:429.591NSD2-PWWP1-IN-3
CAS:<p>NSD2-PWWP1-IN-3 (compound 36) is an effective inhibitor of NSD2-PWWP1, with an IC50 value of 8.05 µM. It has potential applications in cancer research.</p>Formula:C34H39N5O2Color and Shape:SolidMolecular weight:549.706CRV431
CAS:<p>CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).</p>Formula:C67H122N12O13Color and Shape:SolidMolecular weight:1303.76TK-129
<p>TK-129: Oral KDM5B inhibitor, IC50=44 nM, low-toxicity, cardioprotective, aids in heart disease research.</p>Formula:C15H23N5O2Color and Shape:SolidMolecular weight:305.385-Ph-IAA-AM
<p>5-Ph-IAA-AM, eggshell-permeable analog of 5-Ph-IAA, boosts protein degradation in embryos, useful for studying proteins in C. elegans.</p>Formula:C19H17NO4Color and Shape:SolidMolecular weight:323.34(Rac)-Nanatinostat
CAS:<p>(Rac)-Nanatinostat ((Rac)-CHR-3996, example 44) is a potent HDAC inhibitor with an IC50 of less than 330 nM. It exhibits anticancer properties, effectively inhibiting the growth of HeLa, U937, and HUT cells.</p>Formula:C20H19FN6O2Color and Shape:SolidMolecular weight:394.402Sapintoxin D
CAS:<p>Sapintoxin D is a fluorescent phorbol ester and selective activator of protein kinase C.</p>Formula:C30H37NO8Color and Shape:SolidMolecular weight:539.62HDAC6-IN-9
CAS:<p>HDAC6-IN-9 is a γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.</p>Formula:C19H16N2O3Purity:98.84%Color and Shape:SolidMolecular weight:320.34EBET-590
CAS:<p>EBET-590 is a BET inhibitor utilized in cancer research.</p>Formula:C26H26N4O3Molecular weight:442.51AZ-3
CAS:<p>AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).</p>Formula:C20H28FN7Purity:98%Color and Shape:SolidMolecular weight:385.48AMPTX-1
CAS:<p>AMPTX-1 is a molecular glue functioning as a potent, selective, and reversible covalent degrader of BRD9 by recruiting it to the E3 ligase DCAF16.</p>Formula:C42H53N5O4Color and Shape:SolidMolecular weight:691.901EZH2-IN-12
<p>EZH2-IN-12 (Compound 5) is a potent inhibitor of EZH2, which has potential for studies of CNS malignancies.</p>Formula:C23H23Cl2N3O3Color and Shape:SolidMolecular weight:460.35CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Formula:C18H16ClN5OColor and Shape:SolidMolecular weight:353.806PARP1-IN-5
<p>PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research.</p>Formula:C25H24N2O5SColor and Shape:SolidMolecular weight:464.53Pim-1 kinase inhibitor 3
CAS:<p>Pim-1 kinase inhibitor 3 (Compound H5) is a potent inhibitor of Pim-1 kinase, demonstrating an inhibitory concentration (IC50) of 35.13 nM [1].</p>Formula:C20H25N3O2Color and Shape:SolidMolecular weight:339.43EN884
CAS:<p>EN884 is a BRD4 degrader that functions through an SKP1 and proteasome-dependent degradation pathway. It is utilized in the synthesis of proteolysis-targeting chimeras (PROTAC).</p>Formula:C14H18N2OMolecular weight:230.31BRD4 Inhibitor-17
<p>BRD4 Inhibitor-17: Potent with 0.33 μM IC50; modulates gene expression, may counter arsenic toxicity.</p>Formula:C16H16FN3O3SColor and Shape:SolidMolecular weight:349.38O-Desmethyl Midostaurin
CAS:<p>O-Desmethyl Midostaurin is the active Midostaurin metabolite via cytochrome P450 liver enzyme metabolism.</p>Formula:C34H28N4O4Purity:98%Color and Shape:SolidMolecular weight:556.61SMARCA2-IN-6
CAS:<p>SMARCA2-IN-6 is a potent inhibitor of SMARCA2 (also known as BRM), exhibiting an IC50 of less than 5 nM against both SMARCA2 and SMARCA4. Additionally, this compound suppresses the expression of the KRT80 gene in H1299 cells with an IC50 of 26 nM and inhibits the proliferation of SKMEL5 cells carrying a BRG1 mutation with an IC50 value of 13 nM.</p>Formula:C10H8ClF2N5OSColor and Shape:SolidMolecular weight:319.72MS8511
CAS:<p>MS8511: Selective, irreversible G9a/GLP inhibitor. IC50: 100 nM (G9a), 140 nM (GLP). Lowers H3K9me2, anti-proliferative. Useful in cancer/AD/PWS research.</p>Formula:C28H41N5O3Color and Shape:SolidMolecular weight:495.66PARP7-IN-12
CAS:<p>PARP7-IN-12, a potent inhibitor targeting PARP7, exhibits an IC50 of 7.836 nM. This compound is applicable in cancer research.</p>Formula:C23H27ClF3N5O5Color and Shape:SolidMolecular weight:545.94FNDR-20123
<p>FNDR-20123: First safe, effective anti-malarial HDAC inhibitor for Plasmodium (IC50: 31 nM) & human HDACs, with nanomolar potency across several subtypes.</p>Formula:C21H24ClN5O2Color and Shape:SolidMolecular weight:413.9CBP/p300-IN-16
<p>CBP/p300-IN-16 (compound 1) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.61 μM) and LK2 H3K27 (IC50: 2.24 μM).</p>Formula:C26H31N3O4Color and Shape:SolidMolecular weight:449.54SIRT1-IN-5
CAS:<p>SIRT1-IN-5 (215) is a modulator of the NAD-dependent protein deacetylase SIRT1.</p>Formula:C21H17N3O3SColor and Shape:SolidMolecular weight:391.443Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Formula:C25H24N6O3S2Purity:98%Color and Shape:SolidMolecular weight:520.63BET-IN-1
<p>BET-IN-1 is a potent inhibitor of BET, exhibiting good brain permeability and a reasonable metabolic stability.</p>Formula:C23H24ClFN4O3SColor and Shape:SolidMolecular weight:490.98JAK3-IN-11
CAS:<p>JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.</p>Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46CARM1-IN-3 dihydrochloride
<p>CARM1-IN-3 dihydrochloride (17b) is a potent CARM1 inhibitor (IC50: 0.07 μM) with selectivity over CARM3 (IC50 >25 μM).</p>Formula:C24H34Cl2N4O2Color and Shape:SolidMolecular weight:481.46KDOAM-25 trihydrochloride
<p>KDOAM-25 trihydrochloride selectively inhibits KDM5 enzymes, boosts H3K4 methylation, and suppresses MM1S cell growth.</p>Formula:C15H28Cl3N5O2Color and Shape:SolidMolecular weight:416.77LSD1-IN-19
<p>LSD1-IN-19 is a potent, selective LSD1 inhibitor with Ki of 0.108 μM and 72h IC50 values of 0.17-0.40 μM.</p>Formula:C33H42N6O2Color and Shape:SolidMolecular weight:554.73CFT8634
CAS:<p>CFT8634 degrades BRD9, for synovial sarcoma and SMARCB1 tumor research, from patent WO2021178920A1.</p>Formula:C37H45F3N6O5Color and Shape:SolidMolecular weight:710.79P300 bromodomain-IN-1
<p>P300 bromodomain-IN-1 blocks c-Myc, induces G1/G0 arrest, apoptosis. Potent EP300 inhibitor (IC50: 49 nM).</p>Formula:C29H31ClN4O4Color and Shape:SolidMolecular weight:535.03SCH-1473759
CAS:<p>SCH-1473759 is an inhibitor of the aurora (IC50s: 4 and 13 nM for Aurora A and B, respectively).</p>Formula:C20H26N8OSPurity:98%Color and Shape:SolidMolecular weight:426.54QCA570
CAS:<p>QCA570 is an effective BET degrader based on PROTAC (IC50: 10 nM for BRD4 BD1 Protein).</p>Formula:C39H33N7O4SPurity:98%Color and Shape:SolidMolecular weight:695.79Londamocitinib
CAS:<p>Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.</p>Formula:C28H31F2N7O4SPurity:98.64% - 99.56%Color and Shape:SolidMolecular weight:599.65MAO A/HDAC-IN-1
<p>MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.</p>Formula:C21H24ClN3O3Color and Shape:SolidMolecular weight:401.89BRD4 D1-IN-2
<p>BRD4 D1-IN-2 (compound 26), a BRD4 D1 inhibitor, IC50 <0.092 μM, 15 nM affinity, >500x selectivity over BRD2 D1/BRD4 D2.</p>Formula:C33H39F3N6OColor and Shape:SolidMolecular weight:592.7HDAC6-IN-12
<p>HDAC6-IN-12 is a potent inhibitor of HDAC6 that binds in the DNA chain, causing DNA damage and exhibiting anticancer effects that can be used in cancer research</p>Formula:C24H39F2N3O5Color and Shape:SolidMolecular weight:487.58Balanol
CAS:<p>Balanol is an ATP-competitive Protein Kinase C and Protein Kinase A inhibitor.</p>Formula:C28H26N2O10Color and Shape:SolidMolecular weight:550.51Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Formula:C20H20F2N8OColor and Shape:SolidMolecular weight:426.42Tyk2-IN-14
CAS:<p>Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].</p>Formula:C22H21N9O2Color and Shape:SolidMolecular weight:443.46PARP-1-IN-1
<p>PARP-1-IN-1: Selective, oral PARP-1 inhibitor with 0.96 nM IC50; well-tolerated and effective in single-dose MDA-MB-436 model.</p>Formula:C23H25FN4OColor and Shape:SolidMolecular weight:392.47B026
CAS:<p>B026: Oral p300/CBP HAT inhibitor, IC50: p300 1.8 nM, CBP 9.5 nM; targets AR+ prostate cancer cells.</p>Formula:C27H23F4N5O4Color and Shape:SolidMolecular weight:557.5Pim-1 kinase inhibitor 6
CAS:<p>Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].</p>Formula:C21H10BrCl2N3Color and Shape:SolidMolecular weight:455.13DS44470011
CAS:<p>DS44470011 is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) with oral bioavailability. It enhances the release of erythropoietin (EPO) from cells and is utilized in research related to renal anemia.</p>Formula:C21H19N3O4Color and Shape:SolidMolecular weight:377.39IBL-302
CAS:<p>IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].</p>Formula:C25H18FN5O4S3Color and Shape:SolidMolecular weight:567.64SE-7552
CAS:<p>SE-7552, a derivative of 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO), serves as an orally active, highly selective non-hydroxamate HDAC6 inhibitor, boasting an IC50 of 33 nM. It exhibits over 850-fold selectivity against all other known HDAC isozymes. Demonstrating efficacy in vivo, SE-7552 effectively inhibits the growth of multiple myeloma. Additionally, it functions as an anti-obesity agent in diet-induced obese mice [1] [2].</p>Formula:C15H12F3N5OColor and Shape:SolidMolecular weight:335.28Menin-MLL inhibitor 26
CAS:<p>Menin-MLL inhibitor 26: Active reference, inhibits cell growth, used in leukemia research.</p>Formula:C27H29F3N6O3SColor and Shape:SolidMolecular weight:574.62EED ligand 1
<p>EED ligand 1: potent PRC2 inhibitor targeting EED subunit.</p>Formula:C19H19FN8OColor and Shape:SolidMolecular weight:394.41MDH1/2-IN-1
CAS:<p>MDH1/2-IN-1 is an MDH1/2 inhibitor with IC50 values of 1.07 nM and 1.06 nM, respectively. It suppresses mitochondrial respiration and the HIF-1α pathway. MDH1/2-IN-1 exhibits significant antitumor potential and offers new avenues for developing drugs targeting cancer metabolism.</p>Formula:C25H33NO4Color and Shape:SolidMolecular weight:411.534JAK1/TYK2-IN-4
CAS:<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>Formula:C17H23N7OColor and Shape:SolidMolecular weight:341.41WDR5-IN-5
CAS:<p>WDR5-IN-5: Selective oral inhibitor for WDR5's WIN site with high affinity (Ki<0.02 nM) and anti-cancer properties. Good pharmacokinetics.</p>Formula:C29H29F3N6OColor and Shape:SolidMolecular weight:534.58Aurora inhibitor 1
CAS:<p>Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).</p>Formula:C23H25N9SPurity:98%Color and Shape:SolidMolecular weight:459.57BET-IN-8
<p>BET-IN-8 (Compound 27) is a potent inhibitor of BET (Ki: 0.83 μM, Kd: 0.571 μM), which ameliorates LPS-induced sepsis in vivo.BET-IN-8 has shown potential in</p>Formula:C22H21N3O4SColor and Shape:SolidMolecular weight:423.48GSK8814
CAS:<p>GSK8814 is a selective and ATAD2/2B bromodomain chemical probe and inhibitor (binding constant pKd=8.1 and a pKi=8.9 in BROMOscan).</p>Formula:C28H35F2N5O3Purity:98%Color and Shape:SolidMolecular weight:527.61Basroparib
CAS:<p>Basroparib is an inhibitor of ribose polymerase (PARP) and has shown antitumour effects.</p>Formula:C18H21F2N7O3Color and Shape:SolidMolecular weight:421.4BRD-7880
CAS:<p>BRD-7880 is a potent and highly specific inhibitor of aurora kinases B and C.</p>Formula:C32H38N4O7Color and Shape:SolidMolecular weight:590.67PRMT5-IN-1 hydrochloride
<p>PRMT5 IN-1 hydrochloride is a potent PRMT5 inhibitor (IC50: 11 nM), forms covalent adduct with C449, and converts to an aldehyde in vivo.</p>Formula:C19H20Cl2N4O5Color and Shape:SolidMolecular weight:455.29DS17701585
<p>DS17701585: Oral EP300/CBP inhibitor; potent on CBP, EP300, H3K27, & SOX2; useful for cancer research.</p>Formula:C24H26N4O5SColor and Shape:SolidMolecular weight:482.55Tyk2-IN-15
CAS:<p>Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].</p>Formula:C21H25F2N7OColor and Shape:SolidMolecular weight:429.47BRD4-BD1/2-IN-2
CAS:<p>BRD4-BD1/2-IN-2 inhibits BRD4 BD1/BD2 with IC50 <300 nM/<0.5 nM (WO2021233371A1).</p>Formula:C30H33N5O4Color and Shape:SolidMolecular weight:527.61HDAC2-IN-1
<p>HDAC2-IN-1 is an oral HDAC2 inhibitor (IC50: 0.5 μM), crosses the blood-brain barrier, and inhibits HDAC1 and HDAC8.</p>Formula:C22H23ClN4OSColor and Shape:SolidMolecular weight:426.96PRMT5-IN-18
CAS:<p>PRMT5-IN-18 (Compound 002) is a potent inhibitor of PRMT5 and can be used in the study of PRMT5-mediated diseases, such as tumours.</p>Formula:C32H42N4O4Color and Shape:SolidMolecular weight:546.70HDAC-IN-33
<p>HDAC-IN-33 inhibits HDAC1/2/6 (IC50: 24/46/47 nM), exhibits potent antitumor activity in vitro and in vivo, and activates antitumor immunity.</p>Formula:C21H25N3O3Color and Shape:SolidMolecular weight:367.44MTL-CEBPA
<p>MTL-CEPBA is a small activating RNA that targets C/EBPα upregulation and exhibits anti-inflammatory and anti-cancer effects.</p>Color and Shape:SolidAurora A inhibitor 1
CAS:<p>Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)</p>Formula:C25H28ClF2N5O2Color and Shape:SolidMolecular weight:503.97ORIC-944
CAS:<p>ORIC-944 is an orally available, selective variant of PRC2 with anticancer activity for the study of prostate cancer.</p>Formula:C26H25FN6OPurity:98.08%Color and Shape:SolidMolecular weight:456.52Pocenbrodib
CAS:<p>Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.</p>Formula:C28H32FN3O6Purity:98.48% - 99.54%Color and Shape:SolidMolecular weight:525.57GSK3368715 dihydrochloride
CAS:<p>GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is a PRMTs inhibitor , with anticancer activity, for the study of advanced solid tumors.</p>Formula:C20H40Cl2N4O2Purity:99.66% - 99.66%Color and Shape:SolidMolecular weight:439.46LLY-283
CAS:<p>LLY-283, PRMT5 inhibitor, IC50 22 nM, Kd 6 nM, oral, selective, with antitumor effects.</p>Formula:C17H18N4O4Purity:99.49%Color and Shape:SolidMolecular weight:342.35DN02
<p>DN02: a potent, selective BRD8(1) bromodomain probe; Ki=32 nM; 30x more affine than BRD8(2).</p>Formula:C22H24FN3O3Purity:98.22% - 99.74%Color and Shape:SolidMolecular weight:397.44EZM0414
CAS:<p>EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay.</p>Formula:C22H29FN4O2Purity:99.58%Color and Shape:SolidMolecular weight:400.49INCB054329
CAS:<p>INCB054329 is a BET inhibitor targeting BRD2/3/4 and BRDT with IC50s ranging from 1-119 nM.</p>Formula:C19H16N4O3Purity:99.52%Color and Shape:SolidMolecular weight:348.36AMG-193
CAS:<p>AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.</p>Formula:C22H19F3N4O3Purity:99.52%Color and Shape:SolidMolecular weight:444.41BRD0639
CAS:<p>BRD0639 is a first-in-class PRMT5-substrate interaction inhibitor for PBM-dependent PRMT5 activity studies.</p>Formula:C21H22ClN5O4SPurity:99.85%Color and Shape:SolidMolecular weight:475.95Sinefungin
CAS:<p>Sinefungin (Adenosyl-Ornithine) is an effective inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral</p>Formula:C15H23N7O5Purity:98.12%Color and Shape:SolidMolecular weight:381.39JDTic
CAS:<p>JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.</p>Formula:C28H39N3O3Color and Shape:SolidMolecular weight:465.63
